FDA Inspection 1047471 — Sciegen Pharmaceuticals Inc
The FDA completed an inspection of Sciegen Pharmaceuticals Inc on March 14, 2018 in Hauppauge, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 14, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hauppauge, NY (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)